Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Galmed Pharmaceuticals ( (GLMD) ).
On April 14, 2026, Galmed Pharmaceuticals announced a research collaboration with Ramot at Tel Aviv University to evaluate a brain-penetrating form of its SCD1 inhibitor Aramchol as a targeted therapy for metastatic brain cancers. The project will leverage genomic expertise from the Ben-David Lab and advanced 3D tumor and in vivo metastasis models from the Satchi-Fainaro Lab to test Aramchol in p53-deficient brain metastases, potentially extending its relevance to colorectal cancer work at Virginia Commonwealth University’s Massey Comprehensive Cancer Center.
Recent TAU research has shown that p53 inactivation drives brain metastasis via SCD1 upregulation and altered fatty acid metabolism, making SCD1 a critical metabolic vulnerability in p53-deficient tumors. By aiming to exploit this pathway with a first-in-class brain-penetrant SCD1 inhibitor, the collaboration could reposition Galmed from a liver-focused player toward a broader oncology franchise, sharpening its profile in high-unmet-need CNS and metastatic cancers and offering new optionality for investors if preclinical validation is successful.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, recurring losses, and negative free cash flow with declining equity). Technicals also lean bearish with price below key moving averages and a negative MACD, while valuation remains difficult to support due to negative earnings and no indicated dividend yield.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing its lead drug candidate Aramchol, historically aimed at liver disease and GI oncological therapeutics. The company is now seeking to expand Aramchol’s use into oncological indications beyond NASH and fibrosis, while exploring additional cardiometabolic and innovative drug candidates aligned with its core development expertise.
Average Trading Volume: 3,086,640
Technical Sentiment Signal: Sell
Current Market Cap: $4.89M
See more data about GLMD stock on TipRanks’ Stock Analysis page.